A de novo frameshift pathogenic variant in TBR1 identified in autism without intellectual disability.


Journal

Human genomics
ISSN: 1479-7364
Titre abrégé: Hum Genomics
Pays: England
ID NLM: 101202210

Informations de publication

Date de publication:
18 09 2020
Historique:
received: 09 07 2019
accepted: 31 08 2020
entrez: 19 9 2020
pubmed: 20 9 2020
medline: 21 10 2021
Statut: epublish

Résumé

In order to be able to provide accurate genetic counseling to patients with Autism Spectrum Disorder (ASD), it is crucial to identify correlations between heterogeneous phenotypes and genetic alterations. Among the hundreds of de novo pathogenic variants reported in ASD, single-nucleotide variations and small insertions/deletions were reported in TBR1. This gene encodes a transcription factor that plays a key role in brain development. Pathogenic variants in TBR1 are often associated with severe forms of ASD, including intellectual disability and language impairment. Adults diagnosed with ASD but without intellectual disability (diagnosis of Asperger syndrome, according to the DSM-IV) took part in a genetic consultation encompassing metabolic assessments, a molecular karyotype and the screening of a panel of 268 genes involved in intellectual disability, ASD and epilepsy. In addition, the patient reported here went through a neuropsychological assessment, structural magnetic resonance imaging and magnetic resonance spectroscopy measurements. Here, we report the case of a young adult male who presents with a typical form of ASD. Importantly, this patient presents with no intellectual disability or language impairment, despite a de novo heterozygous frameshift pathogenic variant in TBR1, leading to an early premature termination codon (c.26del, p.(Pro9Leufs*12)). Based on this case report, we discuss the role of TBR1 in general brain development, language development, intellectual disability and other symptoms of ASD. Providing a detailed clinical description of the individuals with such pathogenic variants should help to understand the genotype-phenotype relationships in ASD.

Sections du résumé

BACKGROUND
In order to be able to provide accurate genetic counseling to patients with Autism Spectrum Disorder (ASD), it is crucial to identify correlations between heterogeneous phenotypes and genetic alterations. Among the hundreds of de novo pathogenic variants reported in ASD, single-nucleotide variations and small insertions/deletions were reported in TBR1. This gene encodes a transcription factor that plays a key role in brain development. Pathogenic variants in TBR1 are often associated with severe forms of ASD, including intellectual disability and language impairment.
METHODS
Adults diagnosed with ASD but without intellectual disability (diagnosis of Asperger syndrome, according to the DSM-IV) took part in a genetic consultation encompassing metabolic assessments, a molecular karyotype and the screening of a panel of 268 genes involved in intellectual disability, ASD and epilepsy. In addition, the patient reported here went through a neuropsychological assessment, structural magnetic resonance imaging and magnetic resonance spectroscopy measurements.
RESULTS
Here, we report the case of a young adult male who presents with a typical form of ASD. Importantly, this patient presents with no intellectual disability or language impairment, despite a de novo heterozygous frameshift pathogenic variant in TBR1, leading to an early premature termination codon (c.26del, p.(Pro9Leufs*12)).
CONCLUSION
Based on this case report, we discuss the role of TBR1 in general brain development, language development, intellectual disability and other symptoms of ASD. Providing a detailed clinical description of the individuals with such pathogenic variants should help to understand the genotype-phenotype relationships in ASD.

Identifiants

pubmed: 32948248
doi: 10.1186/s40246-020-00281-5
pii: 10.1186/s40246-020-00281-5
pmc: PMC7501624
doi:

Substances chimiques

Codon, Nonsense 0
T-Box Domain Proteins 0
TBR1 protein, human 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

32

Références

Nature. 2012 Apr 04;485(7397):246-50
pubmed: 22495309
Nature. 2012 Apr 04;485(7397):242-5
pubmed: 22495311
Nat Genet. 2014 Aug;46(8):881-5
pubmed: 25038753
Autism Res. 2019 Apr;12(4):562-575
pubmed: 30632707
Mol Autism. 2014 Feb 18;5(1):14
pubmed: 24548729
PLoS Genet. 2014 Oct 30;10(10):e1004772
pubmed: 25356899
Biol Psychiatry. 2002 Oct 15;52(8):805-10
pubmed: 12372652
Eur J Hum Genet. 2016 May;24(5):681-9
pubmed: 26306640
Hum Mutat. 2006 Oct;27(10):1024-9
pubmed: 16941470
Eur J Med Genet. 2018 Dec;61(12):759-764
pubmed: 30268909
Mol Autism. 2015 Feb 27;6:9
pubmed: 25745553
J Autism Dev Disord. 2013 Apr;43(4):775-84
pubmed: 22832890
Mol Autism. 2019 Feb 11;10:5
pubmed: 30792833
Nat Neurosci. 2017 Aug;20(8):1043-1051
pubmed: 28628100
Nat Genet. 2019 Mar;51(3):431-444
pubmed: 30804558
J Autism Dev Disord. 2018 May;48(5):1549-1565
pubmed: 29189917
Mol Autism. 2014 Sep 16;5(1):48
pubmed: 25264479
Front Cell Neurosci. 2014 Sep 10;8:280
pubmed: 25309323
Autism Res. 2015 Aug;8(4):412-26
pubmed: 25600067
J Autism Dev Disord. 2013 May;43(5):1178-83
pubmed: 23015111
Front Neurosci. 2015 Nov 03;9:406
pubmed: 26578866
J Psychiatry Neurosci. 2017 Jan;42(1):37-47
pubmed: 28234597
J Child Psychol Psychiatry. 1989 May;30(3):405-16
pubmed: 2745591
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Neuroscientist. 2012 Oct;18(5):467-86
pubmed: 22547529
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Autism Dev Disord. 1989 Jun;19(2):185-212
pubmed: 2745388
Nat Neurosci. 2014 Feb;17(2):240-7
pubmed: 24441682
Nat Med. 2016 Apr;22(4):345-61
pubmed: 27050589
Nat Commun. 2015 May 18;6:7168
pubmed: 25981743
Neuron. 2001 Feb;29(2):309-11
pubmed: 11239419
Int J Mol Sci. 2016 Sep 19;17(9):
pubmed: 27657040
Nat Rev Genet. 2017 Jun;18(6):362-376
pubmed: 28260791
Nat Neurosci. 2017 Apr;20(4):602-611
pubmed: 28263302
J Med Genet. 2011 Nov;48(11):741-51
pubmed: 21954287
Neuron. 2001 Feb;29(2):353-66
pubmed: 11239428
Nat Commun. 2014 Sep 18;5:4954
pubmed: 25232744
J Neurosci. 2005 Jan 5;25(1):247-51
pubmed: 15634788
Nature. 2014 Nov 13;515(7526):209-15
pubmed: 25363760
Mol Autism. 2012 Oct 15;3(1):9
pubmed: 23067556
Mol Autism. 2013 Dec 09;4(1):48
pubmed: 24321478
Sci Rep. 2018 Sep 24;8(1):14279
pubmed: 30250039
Eur J Med Genet. 2018 May;61(5):253-256
pubmed: 29288087
Science. 2012 Dec 21;338(6114):1619-22
pubmed: 23160955
MMWR Surveill Summ. 2016 Apr 01;65(3):1-23
pubmed: 27031587
Mol Syndromol. 2012 Sep;3(3):102-112
pubmed: 23112752
Genome Res. 2016 Aug;26(8):1013-22
pubmed: 27325115
J Autism Dev Disord. 2001 Feb;31(1):5-17
pubmed: 11439754
J Neurochem. 2004 Dec;91(6):1483-92
pubmed: 15584924
Nat Commun. 2014 Nov 24;5:5595
pubmed: 25418537
Nature. 2012 Apr 04;485(7397):237-41
pubmed: 22495306
Trends Genet. 2009 Apr;25(4):166-77
pubmed: 19304338

Auteurs

Laurie-Anne Sapey-Triomphe (LA)

Lyon Neuroscience Research Center, Brain Dynamics and Cognition team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.
Laboratory of Experimental Psychology, Department of Brain and Cognition, Leuven Brain Institute, KU Leuven, Leuven, Belgium.

Julie Reversat (J)

Lyon Hospitals, Genetics Service and National Reference Centre for Developmental Anomalies, Lyon, France.

Gaëtan Lesca (G)

Lyon Hospitals, Genetics Service and National Reference Centre for Developmental Anomalies, Lyon, France.
Lyon Neuroscience Research Center, Genetics of Neurodevelopment team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.

Nicolas Chatron (N)

Lyon Hospitals, Genetics Service and National Reference Centre for Developmental Anomalies, Lyon, France.
Lyon Neuroscience Research Center, Genetics of Neurodevelopment team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.

Marina Bussa (M)

Centre de Ressource Autisme Rhône-Alpes, Centre Hospitalier Le Vinatier, Bron, France.
Hôpital Saint-Jean-de-Dieu, Lyon, France.

Sylvie Mazoyer (S)

Lyon Neuroscience Research Center, Genetics of Neurodevelopment team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.

Christina Schmitz (C)

Lyon Neuroscience Research Center, Brain Dynamics and Cognition team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France. christina.schmitz@inserm.fr.

Sandrine Sonié (S)

Lyon Neuroscience Research Center, Brain Dynamics and Cognition team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.
Centre de Ressource Autisme Rhône-Alpes, Centre Hospitalier Le Vinatier, Bron, France.
Hôpital Saint-Jean-de-Dieu, Lyon, France.

Patrick Edery (P)

Lyon Hospitals, Genetics Service and National Reference Centre for Developmental Anomalies, Lyon, France.
Lyon Neuroscience Research Center, Genetics of Neurodevelopment team, INSERM UMRS 1028, CNRS UMR 5292, Université Claude Bernard Lyon 1, Université de Lyon, F-69000, Lyon, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH